Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.79 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.79 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.72 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.72 |
| ▸ | NT5E | P21589 | 15/20 | 0.56 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20266301 | 0.88 | TAS1R3 (1.00) | TAS1R3TAS1R1P2RX3P2RX2RNASEL | |
| SCHEMBL20282630 | 0.88 | TAS1R3 (1.00) | TAS1R3TAS1R1P2RX3P2RX2RNASEL | |
| SCHEMBL20277494 | 0.88 | TAS1R3 (1.00) | TAS1R3TAS1R1P2RX3P2RX2RNASEL | |
| SCHEMBL20277542 | 0.88 | TAS1R3 (1.00) | TAS1R3TAS1R1P2RX3P2RX2RNASEL | |
| SCHEMBL30969959 | 0.87 | TAS1R3 (0.98) | TAS1R3TAS1R1P2RX3P2RX2RNASEL | |
| SCHEMBL21882901 | 0.86 | TAS1R3 (0.59) | TAS1R3TAS1R1P2RX3P2RX2NT5E | |
| SCHEMBL29395130 | 0.85 | P2RX3 (0.98) | TAS1R3TAS1R1P2RX3P2RX2RNASEL | |
| SCHEMBL29601540 | 0.84 | P2RX3 (1.00) | TAS1R3TAS1R1P2RX3P2RX2RNASEL | |
| SCHEMBL10021603 | 0.84 | P2RX3 (1.00) | TAS1R3TAS1R1P2RX3P2RX2RNASEL | |
| SCHEMBL840111 | 0.83 | P2RX3 (0.88) | TAS1R3TAS1R1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | TAS1R3 3522/4885TAS1R1 3109/4885P2RX3 37/4885 |
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | TAS1R3 2590/4885TAS1R1 2798/4885P2RX3 14/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | TAS1R3 3522/4885TAS1R1 3109/4885P2RX3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.